A Phase 1 Study of Sgnalpv in Advanced Solid Tumors
Research payments
$63,682
Through program year 2025, $63,682 in research payments was reported against A Phase 1 Study of Sgnalpv in Advanced Solid Tumors, across 31 payments, paid by Pfizer Inc..
- Paid by
- Pfizer Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $500 | 1 |
| 2024 | Research | $63,182 | 30 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Patricia Lo Russo New Haven, CT Named on 8 payments
- Kathleen Moore Oklahoma City, OK Named on 7 payments
- Justin Call West Valley City, UT Named on 5 payments
- Nehal Lakhani Grand Rapids, MI Named on 4 payments
- Alexander Spira Fairfax, VA Named on 3 payments
- Cesar Batista Orlando, FL Named on 3 payments
- Li Ge Clovis, CA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.